In conclusion, attenuation of the hepatic steatosis by pioglitazone may be conferred by refining insulin sensitivity, intensifying cytosolic lipolysis, β-oxidation and lipophagy-mediated lysosomal lipolysis in a manner of PPARα/γ dependently. This evidence concerns the gene INS and fatty liver disease.